NATA Accredits ColoSTAT Clinical Testing Service
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Rhythm Biosciences Limited has announced that its ColoSTAT® clinical testing service has received accreditation from the National Association of Testing Authorities (NATA), confirming it meets international standards for quality and competence. This accreditation allows Rhythm to offer ColoSTAT® as an accredited diagnostic testing service across Australia, marking a significant regulatory milestone for the company. The company plans to expand clinician awareness and referral pathways as part of its commercial rollout strategy for ColoSTAT® testing services.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- RHY Executes SE Asian Genetype Distribution Agreement
- Exercise of RHYO Options underwritten for $4.5m to $6.0m
- Trading Halt
- Half-Year Financial Report and Appendix 4D
- Rhythm Bio enters ColoSTAT agreement with 4Cyte Pathology
Later from Rhythm Biosciences
- First ColoSTAT Clinical Test Sale
- Response to ASX Query Letter
- FY26 Appendix 4E & Audited Financial Report
- Initial ColoSTAT Assessment in UK opens new market access
- ColoSTAT Economic Study - Australian Public Health Savings
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences